Group 1 - Zhonghui Biotech (02627) has successfully held the launch meeting for the Phase III clinical trial of its lyophilized human rabies vaccine (human diploid cells) in Hubei, marking a significant step towards successful commercialization of this core product [1] - Rabies is a zoonotic disease caused by the rabies virus (RABV), with a widespread geographical distribution affecting over 150 countries and regions, posing a severe threat to human life due to nearly 100% mortality once symptoms appear [1] - The onset of rabies symptoms is related to the speed at which the virus moves to the central nervous system, typically occurring 20 to 60 days post-infection, leading to acute encephalomyelitis and subsequent respiratory and circulatory failure [1] Group 2 - Currently, there is no effective treatment for rabies, making prevention crucial, with vaccination being the most effective control measure [2] - Human diploid cell rabies vaccine (HDCV) has a history of over 40 years of use in Europe and North America, with its safety and efficacy well-validated, recognized internationally as the "gold standard" for rabies vaccines [2] - The lyophilized human rabies vaccine (human diploid cells) has completed Phase I clinical trials, showing good safety profiles for both the Essen and Zagreb vaccination protocols in individuals aged 10 to 60 [2]
中慧生物冻干人用狂犬病疫苗(人二倍体细胞)Ⅲ期临床试验正式启动